Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent News

Mar 29, 2017
London, UK, 29 March 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Completed Phase 3
Epidiolex
Lennox-Gastaut Syndrome
Completed Phase 3
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (Partnered)

Sativex
Ms Spasticity
Approved